Skip to main content

More Than Half of Infants Protected by Maternal RSV Vaccine, Nirsevimab, or Both

Medically reviewed by Carmen Pope, BPharm. Last updated on Sep 29, 2024.

By Elana Gotkine HealthDay Reporter

FRIDAY, Sept. 27, 2024 -- In the 2023 to 2024 respiratory syncytial virus (RSV) season, more than half of infants were protected by maternal RSV vaccine, nirsevimab, or both, according to research published in the Sep. 26 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.

Hilda Razzaghi, Ph.D., from the CDC in Atlanta, and colleagues conducted an internet survey panel during March 26 to April 11, 2024, to examine maternal and infant RSV immunization coverage for the 2023 to 2024 RSV season.

The researchers found that 32.6 percent of 678 women at 32 to 36 weeks of gestation during September 2023 to January 2024 reported receipt of an RSV vaccine during pregnancy. Overall, 44.6 percent of 866 women with an infant born during August 2023 to March 2024 reported infant receipt of nirsevimab. More than half (55.8 percent) of infants were protected by maternal RSV vaccine, nirsevimab, or both. There was an association seen for provider recommendation for maternal vaccination or infant nirsevimab with higher immunization coverage; the main reason for not getting RSV immunization was lack of a provider recommendation. Concern about long-term safety for the infant was the main reason for definitely or probably not getting nirsevimab for infants.

"Recommendations from health care providers are critical to improving RSV immunization coverage for both pregnant women and their infants and reducing severe RSV disease among infants," the authors write.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

RSV Vaccines, Nirsevimab Tied to Reduced RSV-Linked Hospitalization

TUESDAY, May 13, 2025 -- Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated hospitalization rates among...

Nirsevimab Effective for Reducing Burden of RSV in Infants

THURSDAY, May 8, 2025 -- Nirsevimab is effective for reducing the burden of respiratory syncytial virus (RSV) in infants in real-world settings, according to a study published...

72 Percent of Infants Immunized Against Respiratory Syncytial Virus

TUESDAY, May 6, 2025 -- In a recent study of a population of infants, published online May 6 in Pediatrics, 72 percent of infants were found to be immunized against respiratory...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.